ClinicalTrials.gg
Not yet recruitingNCT07575568REMODEL IUpdated May 8, 2026

Revascularization With Modification Using Definitive IVL and Serration Remodeling for Optimal Lumen

An interventional study of Serranator Sonic Intravascular Lithotripsy (IVL) System in Peripheral Artery Disease, sponsored by Cagent Vascular LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Cagent Vascular LLC · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The objective of this first-in-human study is to assess the safety and effectiveness of the Serranator Sonic Intravascular Lithotripsy (IVL) System™ for the treatment of peripheral artery disease.

02

Conditions studied

  • Peripheral Artery Disease
03

In context

Peripheral Arterial Disease

1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.

This study's planned enrollment of 30 is below the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.

Browse Peripheral Arterial Disease studies →

Lead sponsor

Cagent Vascular LLC is the lead sponsor of 7 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

*Inclusion Criteria for Cohort A: ATK arm of the study:

Clinical:

  • Subject is ≥ 18 years of age
  • Target limb is Rutherford Clinical Category 2, 3 or 4
  • Resting ABI of ≤0.90, or TBI ≤0.70 of the target limb

Angiographic:

  • Subject must have a de novo target lesion in a native superficial femoral artery (SFA) or popliteal artery
  • Reference vessel diameter (RVD) between 4.0 and 8.0mm
  • Target lesion must have a diameter stenosis of ≥70%
  • Lesion calcification is at least moderate
  • Total planned target lesion length must be ≤150mm
  • Chronic total occlusion lesion length is ≤100mm
  • Subject has at least one patent tibial vessel on the target limb with runoff to the foot

    • Exclusion Criteria for Cohort A: ATK arm of the study:

Clinical:

  • Rutherford Clinical Categories 0, 1, 5 and 6
  • Subject with known pregnancy or is nursing
  • Subject has acute or chronic renal disease, defined as serum creatinine of >2.5 mg/dL or >220 µmol/L or on dialysis

Angiographic:

  • Target lesions >150mm by visual estimation
  • Chronic total occlusions > 100mm by visual estimation
  • No or mild calcium present in the target lesion

    • Inclusion Criteria for Cohort B: BTK arm of the study:

Clinical:

  • Age of subject is ≥18
  • Rutherford Clinical Category 2 - 5 (with tissue loss limited to the digits and no evidence of infection)

Angiographic:

  • Single or two target lesion(s) located in a de novo artery distal to the trifurcation vessels
  • Target vessel reference diameter is between 2.5mm and 4.0 mm
  • Target lesion with diameter stenosis ≥50%
  • Target lesion is ≤150mm in length
  • Subject has at least one patent tibial vessel (>50%) with run-off to the foot.
  • Calcification is at least moderate

    • Exclusion Criteria for Cohort B: BTK arm of the study:

Clinical:

  • Rutherford Clinical Category 0,1 or 6
  • Gangrene of the lower extremity
  • Patient is pregnant or nursing

Angiographic:

  • Target lesion is within only lower extremity vessel with \< 50% stenosis
  • Target lesion length exceeds 150mm
  • Patient has chronic total occlusion of target lesion
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Above-the-Knee

    For blockages in the legs that occur above the knee.

    Device: Serranator Sonic Intravascular Lithotripsy (IVL) System

  • Experimental
    Below-the-Knee

    For blockages in the legs that occur below the knee.

    Device: Serranator Sonic Intravascular Lithotripsy (IVL) System

Interventions

  • DeviceSerranator Sonic Intravascular Lithotripsy (IVL) System

    Serration remodeling balloon angioplasty with Intravascular Lithotripsy of the superficial femoral and popliteal arteries for Cohort A: Above-the-Knee; treatment of the infrapopliteal and inframalleolar arteries for Cohort B: Below-the-Knee.

06

What researchers measure

Primary outcomes

  1. Primary Safety: Major Adverse Events

    Primary Safety: Major Adverse Events (MAE), measured at 30 days and defined as a composite of: * All cardiovascular death * Major amputation * Clinically-driven target lesion revascularization (CD-TLR)

    Time frame: 30 Days

  2. Primary Effectiveness: Procedural Success

    Procedural Success, defined as: \<50% residual stenosis of the target lesion (with or without adjunctive PTA therapy and/or stenting) by angiographic core-lab assessment

    Time frame: Procedure

Secondary outcomes

  1. Freedom from Major Adverse Events at 6 months

    Freedom from Major Adverse Events, defined as a composite of all cardiovascular death, major amputation, and clinically-driven target lesion revascularization

    Time frame: 6 months

  2. Freedom from Major Adverse Events at 12 months

    Freedom from Major Adverse Events defined as a composite of all cardiovascular death, major amputation, and clinically-driven target lesion revascularization.

    Time frame: 12 months

  3. Procedural success of ≤30% residual stenosis of the target lesion

    Procedural success of ≤30% residual stenosis of the target lesion (with or without adjunctive PTA therapy and/or stenting) by angiographic core lab assessment

    Time frame: Procedure

  4. Patency rates of target lesion by duplex ultrasound

    Patency rates at 30 days, 6 months, and 12 months of target lesion by duplex ultrasound. Target vessel patency by duplex ultrasound, defined as freedom from \> 50% restenosis, as assessed by duplex ultrasound peak systolic velocity ratio of ≥2.5

    Time frame: 30 Days, 6 Months, and 12 Months

  5. Freedom from clinically-driven target lesion revascularization

    Freedom from clinically-driven target lesion revascularization (CD-TLR) at 30 days, 6 months, and 12 months

    Time frame: 30 Days, 6 Months, and 12 Months

  6. Change in Ankle-Brachial Index/Toe-Brachial Index

    Change in Ankle-Brachial Index/Toe-Brachial Index (TBI) at 30 days, 6 months, and 12 months, as compared to baseline

    Time frame: 30 Days, 6 Months, and 12 Months

  7. Change in Rutherford Category

    Change in Rutherford Category at 30 days, 6 months and 12 months, as compared to baseline

    Time frame: 30 Days, 6 Months, and 12 Months

  8. Change in Walking Impairment Questionnaire score

    Change in Walking Impairment Questionnaire (WIQ) score at 30 days, 6 months and 12 months, as compared to baseline

    Time frame: 30 Days, 6 Months, and 12 Months

  9. Change in EuroQol-5D-3L

    Change in EuroQol-5D-3L (EQ-5D-3L) at 30 days, 6 months and 12 months, as compared to baseline

    Time frame: 30 Days, 6 Months, and 12 Months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for May 2026; primary completion for Aug 2026, 3 months later.

Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's planned 3 months is below that.

Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
May 4, 2026
First posted
May 8, 2026
StartEst.
May 2026
Primary completionEst.
Aug 2026
CompletionEst.
Sep 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07575568
Lead sponsor
Cagent Vascular LLC
Collaborators
Clinical Accelerator, Australian Healthcare Solutions, Yale Cardiovascular Research Group
Responsible party
Sponsor
First posted
May 8, 2026
Start date
May 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Sep 2027 (estimated)
Last update
May 8, 2026

Study contacts

Alexis Shewfelt
Contact
ashewfelt33@cagentvascular.com
650-208-6743
Jennifer Meyers Sullivan
Contact
jsullivan64@cagentvascular.com
219-730-9402

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion